Yirui Biology: Net profit in 2025 is expected to decrease by 19.71% year-on-year, with a proposed cash dividend of 0.2468 yuan.

On April 26th, Innovent Biologics disclosed its annual report, achieving operating revenue of 263 million yuan in 2025, a year-on-year increase of 17.38%; net profit attributable to shareholders was 13.7433 million yuan, a year-on-year decrease of 19.71%; basic earnings per share were 0.03 yuan. The company plans to distribute a cash dividend of 0.2468 yuan for every 10 shares. During the reporting period, the company's food safety rapid testing business and animal diagnostics business segments saw growth in operating revenue; however, factors such as continuous increase in strategic investments in market expansion, disturbances from convertible bond interest, external investments and other non-operating matters, as well as other relevant factors, have put pressure on the company's profit scale compared to the same period last year.